About Us
ACADIA Pharmaceuticals (Nasdaq: ACAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. We are focused on developing a portfolio consisting of four product candidates including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis in collaboration with Biovail. In addition, we have a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and a program in IND-track development in collaboration with Meiji Seika.
All of the product candidates in our pipeline emanate from discoveries made using our proprietary drug discovery platform. We have assembled a strong team of industry-experienced executives to lead the development of our product candidates and we complement this team with a network of world-class scientific and clinical advisors.
back to top